 |
PDBsum entry 6tld
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
ChemMedChem
15:571-584
(2020)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure-Based Design, Synthesis, and Biological Evaluation of Triazole-Based smHDAC8 Inhibitors.
|
|
D.V.Kalinin,
S.K.Jana,
M.Pfafenrot,
A.Chakrabarti,
J.Melesina,
T.B.Shaik,
J.Lancelot,
R.J.Pierce,
W.Sippl,
C.Romier,
M.Jung,
R.Holl.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Schistosomiasis is a neglected tropical disease caused by parasitic flatworms of
the genus Schistosoma, which affects over 200 million people worldwide and leads
to at least 300,000 deaths every year. In this study, initial screening revealed
the triazole-based hydroxamate 2 b
(N-hydroxy-1-phenyl-1H-1,2,3-triazole-4-carboxamide) exhibiting potent
inhibitory activity toward the novel antiparasitic target Schistosoma mansoni
histone deacetylase 8 (smHDAC8) and promising selectivity over the major human
HDACs. Subsequent crystallographic studies of the 2 b/smHDAC8 complex revealed
key interactions between the inhibitor and the enzyme's active site, thus
explaining the unique selectivity profile of the inhibitor. Further chemical
modifications of 2 b led to the discovery of 4-fluorophenoxy derivative 21
(1-[5-chloro-2-(4-fluorophenoxy)phenyl]-N-hydroxy-1H-1,2,3-triazole-4-carboxamide),
a nanomolar smHDAC8 inhibitor (IC50 =0.5 μM), exceeding the
smHDAC8 inhibitory activity of 2 b and SAHA (vorinostat), while exhibiting an
improved selectivity profile over the investigated human HDACs. Collectively,
this study reveals specific interactions between smHDAC8 and the synthesized
triazole-based inhibitors and demonstrates that these small molecules represent
promising lead structures, which could be further developed in the search for
novel drugs for the treatment of schistosomiasis.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |